CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04526834
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:12.938650+00:00
Published At: 2023-04-20T00:00:00+00:00
Record Updated At: 2023-04-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Anaplastic Large Cell Lymphoma", "Peripheral T Cell Lymphoma", "Extranodal NK/T-cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-04-20"
protocolSection.identificationModule.nctId: "NCT04526834"
protocolSection.identificationModule.officialTitle: "Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.